Metsera Acquisition: Pfizer received early U.S. antitrust approval for its $7.3 billion acquisition, with the FTC ending the waiting period. The deal can proceed without additional review.
Legal Action: Pfizer is suing Metsera and Novo Nordisk over Novo’s $8.5 billion takeover bid, claiming it violates antitrust laws and threatens Pfizer’s merger agreement.
Antitrust Lawsuit: A federal judge ordered Pfizer and 35 other drugmakers to face a lawsuit over alleged price-fixing of 80 generic drugs between 2009–2016.